Abstract 14030: Characterization of Lipid Profiles, Lipid Management Medications, Medical Resources Utilization and Health Care Outcomes in Medicare Age Patients With COPD in an Academic Center

• Published in: Circulation (New York, N.Y.) N.Y.), 2022-11, Vol.146 (Suppl_1), p.A14030-A14030
• Main Authors: Bhattarai, Mukul, Deshpande, Radhika, Patel, Raj, Regmi, Manjari R, Kulkarni, Abhishek, Graves, Mark
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/circ.146.suppl_1.14030

IntroductionRecent studies have shown dysregulation in lipid metabolism may contribute to various lung diseases including COPD. The lipid profile in patients with COPD is incompletely understood which may affect the clinical outcomes. ObjectiveTo perform elaborative investigation on lipid profile in COPD patients and clinical outcomes MethodsA retrospective database reviews from single academic medical center ResultsThe study population included 1360 patients, over the age of 65 with a diagnosis of COPD in a 2-year period. The presence of coronary artery disease, cerebrovascular disease, and peripheral artery disease was measured. The variables measured include lipid profile, lipid medications, number of hospitalizations, number of clinic and emergency room visits (Table 1). 38% of COPD patients have cardiovascular disease (CVD) compared to the prevalence of vascular disease in the population as a whole (27%). The average triglyceride (TG) in the patients with COPD was greater than TG in patients without COPD (150 vs. 135, p=.03). 38% of COPD patients with CVD have a TG > 150. 19% of COPD patients with coexisting vascular disease had an LDL >100. Anti-lipid medications in COPD patients were sub-optimally utilized. ConclusionsCOPD patients had poorly controlled lipid profile including elevated TG and LDL levels. These patients are at high risk for adverse events that include CVD, frequent ER visits and hospital readmission. The anti-lipid medications were underutilized. It is highly recommended to identify barriers to optimum care and seek resources and strategy to mitigate difficulties in lipid management in patients with COPD to prevent adverse outcomes.